Centessa Pharmaceuticals (NASDAQ:CNTA) Receives Buy Rating from Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reiterated by Guggenheim in a report issued on Monday,Benzinga reports.

Separately, TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Trading Down 3.0 %

Shares of CNTA stock opened at $17.26 on Monday. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock’s 50 day simple moving average is $16.78 and its two-hundred day simple moving average is $15.54. The company has a market cap of $2.28 billion, a PE ratio of -11.28 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,626,702.06. This trade represents a 13.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 77,705 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $16.39, for a total value of $1,273,584.95. Following the completion of the transaction, the general counsel now owns 125,785 shares of the company’s stock, valued at $2,061,616.15. This trade represents a 38.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 452,652 shares of company stock valued at $7,800,532 in the last quarter. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $20,698,000. Franklin Resources Inc. raised its stake in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after buying an additional 953,659 shares during the last quarter. Baker BROS. Advisors LP raised its stake in shares of Centessa Pharmaceuticals by 123.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company’s stock valued at $19,623,000 after buying an additional 677,966 shares during the last quarter. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $4,951,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.